Lentiviral Vector Production
Enhancing Quality and De-risking Production for Cell & Gene Therapies
Leveraging our deep experience, knowledge, and expertise from more than three decades as a leading viral vector CDMO, we provide comprehensive development and manufacturing solutions from plasmids through fill/finish to support your lentivirus-based therapeutics.
Our VirusExpress® lentivirus platform delivers a high-performance, high-quality solution to de-risk lentivirus production.
Our tailored and flexible approach to tech transfers enables robust, high-quality manufacturing.
Our Track Record
> 1 X 108 TU/mL
Consistent, high titers
< 12
Months to GMP manufacturing
200+ L
Proven, streamlined scalability
300+
Batches of lentiviral vector produced
30+
Years of viral vector development and manufacturing
1
One of the first to support commercially approved CAR-Ts
De-risked Lentivirus Production Through Proven Experience and Comprehensive Solutions
Trusted to advance lentiviral cell and gene therapies for over three decades, we have the expertise and know-how to support your therapeutic from preclinical development through commercialization.
Discover our end-to-end solutions for lentiviral vector, customized to your need and built to meet your timelines:
- Packaging and transfer plasmids
- GMP-banked HEK293T cell line
- Chemically defined cell culture medium
- Optimized GMP production
- On-site fill/finish services
- Comprehensive analytical toolbox
- Regulatory support services
- Tech transfer capabilities
Lentivirus VirusExpress® Platform Advantages
Using VirusExpress® lentivirus platform, our development and manufacturing experts can accelerate your path to clinical and commercial GMP manufacturing by providing streamlined development, scalable manufacturing, and comprehensive analytics.
Proven Performance
- Successfully used in numerous clinical programs
- Multiple INDs in process/filed
Accelerated Timelines
- Less than 12 months to GMP manufacturing
- Save 18 to 20+ months compared to a traditional process timeline
Cost Savings
- Lower operational spend with more productive batches
- Lower cost per dose
Comprehensive Analytics
- 25+ In-house panel of pre-qualified assays
- Customized characterization assays
- Onsite in-process and release testing
Our Experience is Your Success
Trusted to advance lentiviral cell and gene therapies for three decades, we have the expertise and knowhow to support your therapeutic from preclinical development through commercialization.
Contact us to discover how our capabilities for lentivirus development and manufacturing can de-risk and optimize your lentiviral vector program to improve performance, quality, reduce costs, and streamline development to GMP manufacturing in less than 12 months.
Related Resources
- Article: Lentivirus Platform: Optimizing Performance for De-Risked Production
Explore our platform, that was intentionally designed to ensure optimized and de-risked lentivirus production and to better address the needs of cell and gene therapy innovators.
Related Webinars
Hear from our viral vector experts as they showcase our capabilities and solutions for cell and gene therapy production and highlight key features of our technologies and GMP facility.
In this webinar, our innovation scientists explore how they optimized our VirusExpress® platform for lentiviral vectors to maximize titer, while providing a streamlined platform to accelerate development timelines to clinical trials.
In this webinar we share how the superior performance of our scalable, end-to-end VirusExpress® lentivirus platform enables success for your cell or gene therapy.
External Resources
Discover how partnering experienced viral vector CTDMO can help guide you through the complexities of manufacturing and overcome regulatory hurdles to bring new therapies to patients.
Learn how our Manufacturability Assessment can help identify and address development and manufacturing challenges when bringing new therapies to market.
Watch the video and read the poster to learn how we optimized our VirusExpress® platform for lentiviral vectors to maximize titers, enrich recovery, and reduce time to GMP manufacturing.
In this white paper, we outline how DoE studies were used to define and optimize upstream and downstream workflows, establishing the VirusExpress® LV platform as a high quality and performance solution for suspension-based LV vector manufacturing.
To continue reading please sign in or create an account.
Don't Have An Account?